Skip to main content

Table 1 SBRT Thoracic Re-irradiation Studies

From: Stereotactic Body Radiation Therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review

Study Coon et al[24] Kelly et al[21] Trakul et al[22] Reyngold et al[23] Ester et al[25] Trovo et al[27] Seung et al[26]
Number of Patients 12 36 15 39 13 17 8
First Radiation Dose n/a 61.5 Gy (range 30-79.2) Median BED 87.5 Gy (range 60-112.5) 61.0 Gy (30-80) 61.2 Gy (median) 50-60 Gy 50-68 Gy
Time Between Treatments (median) n/a 22.0 mo (range 0-92) 16 mo (range 5-80) 37.0 mo (range 1-180) 19.7 mo (range 4.7-84.7) 18 mo (range 1-60) 367.0 mo (range 8-57)
Re-irradiation Dose 60 Gy 50 Gy (72%), 40 Gy (17%), Other (11%) median BED 80 Gy (60-112.5) median BED 70.4 Gy (range 42.6-180) 9-10 Gy x5 30 Gy (5-6 fx) 12 Gy x4, 10 Gy x5, 8 Gy x5, 20 Gy x3
Target Size (range) median GTV 14.3 cc tumor (median) 1.7 cm (range 0.6-3.8) 14.2 ml (range 2-57.7) median GTV 19.0 cc (0.7-227) n/a n/a n/a
Follow up (median) 12 mo 15 mo (range 4-45) 15 mo (range 4-65) 12.6 mo (range 1.3-47.5) 11.4 mo (0.9-38.3) 18 mo (range 4-57) 18 mo (range 11-20)
Local Control 92% 92% 65.5% 77% (1-year LPFS) 92% 86% 86%
Overall Survival 67% (1-year) 59% (2-years) 80% (1-year) 22.0 months (MS) n/a 59% (1-year) n/a
Toxicity no G3 G3 pneumonitis (28%), G3 esophagitis (8%), G3 skin (6%), G3 cough (3%), No G4/5 toxicities chest wall pain (6.7%), esophagitis (0.9%), no G2 or higher pneumonitis, no G4 or higher toxicities G2 pulmonary (18%), G3 pulmonary (5%), G2/3 chest wall pain (18%), G2/3 fatigue (15%), G2-4 skin toxicity (5%), no G5 toxicities G2 pulmonary (7.7%), G3 pulmonary (7.7%), no G4 or G5 G3 pneumonitis (23%), G5 pneumonitis (6%), G5 hemoptysis (6%) G1 cough (13%), G1 pain (13%), G2 dyspnea (100%)
  1. n/a: not available; mo: months; G: grade.